Millennium Pharmaceuticals, The Takeda Oncology Company, and Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) approved VELCADE for patients with previously untreated multiple myeloma (MM). The Company's co-development partner, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) also has filed a corresponding application with the European Medicines Evaluation Agency (EMEA).
The details can be read here.
No comments:
Post a Comment